Syngene is paying $36.5 million to acquire Emergent's shuttered biologics facility in the Bayview neighborhood of Baltimore, the Indian drugmaker said (PDF) Monday.
Reuters on MSN13d
India's Syngene International acquires first US biologics facility for $36.5 million(Reuters) -India's Syngene International on Monday said it has acquired its first biologics facility in the United States ...
BANGALORE, India, March 10, 2025 /PRNewswire/ -- Syngene International Limited ('Syngene'), a global contract research, development, and manufacturing organization ...
Syngene International a global contract research, development, and manufacturing organization (CRDMO), announced the acquisition of its first biologics site in the USA, fitted with multiple monoclonal ...
Bangalore, March 10, 2025: Syngene International Limited (‘Syngene’), a global contract research, development, and manufacturing organization (CRDMO), today announced the acquisition of its first ...
Syngene International, the contract research wing of Biocon Group, has acquired its first manufacturing facility in the US from Emergent Manufacturing Operations Baltimore. The pharma player has ...
(MENAFN- PR Newswire) The state-of-the-art biologics facility, acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent manufacturing Operations Baltimore, LLC (a ...
Expected to enhance global innovator flexibility with biologics drug substance facility in Baltimore BANGALORE, India, March 10, 2025 /PRNewswire/ -- Syngene International Limited ('Syngene'), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback